Strategies, regulatory intel, and expert guidance across the full lifecycle of MedTech innovation: concept to commercialization. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­    ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  
View in browser
Logo-White
December 25 Insights from the Cutting Edge of Medtech (2)

Designing a clinical trial without payer evidence built in? You may be setting up a 12–24 month detour after FDA approval. Rushing from proof of concept to detailed design without a formal feasibility gate? That's where budgets blow and timelines collapse. And if your growth strategy has adjacencies on the roadmap, the real question isn't which markets to enter, it's which ones will quietly cannibalize what you've already built. Payer evidence blind spots, medical device UX/UI, preclinical KOL evaluation, design feasibility, and market adjacency strategy are all in this month's featured blogs.


Let us help bring Velocity to your Vision. Every month we share expertise across the innovation pathway and feature conferences where you can meet our experts in person.

INTRODUCING VOICES OF VERANEX

pablo-1

Voices of Veranex, our newest video series, is officially here.

 

In our first episode, Dr. Pablo Morales shares why he joined Veranex after 16 years at the FDA and what makes our team’s diversity of thought and expertise such a strength. 
Watch Full Interview
blog

Software Development Services

 

Build SaMD and SiMD that's ready for market, not just to demo.
 
Schedule a consultation with our software development experts.

 

Learn More

EVENTS: MEET OUR EXPERTS IN PERSON 

View All Events
2-Mar-03-2026-06-11-46-8496-AM
mdma-1

MDMA FDA Forum

March 12–13, 2026 | Washington, DC

hfes2

Human Factors & Ergonomics in Health Care

New York, NY, USA  |  22-25, March 2026

Clinical Investigation of Medical Devices Requirements of ISO 141552020 Good Clinical Practice (2)

INDUSTRY INSIGHTS FROM THE VERANEX BLOG

1-Mar-03-2026-04-47-40-1878-AM

The Unspoken Rules of UX/UI for Medical Device Digital Experience


Don't let seemingly minor interface decisions jeopardize clinical utility, adoption, and patient safety.

2-Mar-03-2026-04-48-24-9952-AM

The Secrets to Finding the Optimal KOLs for Preclinical Work


What do woodworkers, mechanics, sculptors and architects have to do with preclinical testing? Check it out!

3-Mar-03-2026-04-50-51-0739-AM

IVDR Transition Deadline: What to Do If You're Behind 

 

As the IVDR transition deadlines approach (and pass by), the time for waiting is over. You may well be farther behind than you think. Here's how to catch up.

 

4-Mar-03-2026-04-51-43-8005-AM

The Reimbursement Blind Spot That's Stalling Your Device's Market Access

 

Most medical device trials are designed to satisfy regulators. Payers are asking entirely different questions.

 

5-Mar-03-2026-04-52-39-0086-AM

The Development Milestone Most Medical Device Teams Skip — And Pay For Later

 

Jumping from concept to detailed design is a predictable, and preventable, cause of late-stage rework, schedule collapse, and budget overruns.

6-4

Adjacent Markets Are Where MedTech Growth Happens. And Where Capital Goes to Die.

 

The difference between a winning adjacency move and a costly distraction is the rigor of how you decide which opportunities are worth pursuing.

 

Product Design & Engineering
Preclinical & Pathology | Clinical Research (CRO)

 Regulatory Quality | Commercialization

LinkedIn

Veranex Solutions, 5420 Wade Park Blvd., Suite 204, Raleigh, NC 27607, USA

Unsubscribe Manage preferences